摘要
目的 分析盐酸特拉唑嗪联合非那雄胺片治疗对良性前列腺增生患者(BPH)临床疗效、控尿功能及炎性因子的影响。方法 选取成都金沙医院2019年7月至2023年1月收治的良性前列腺增生患者129例,根据治疗方式分为对照组63例(非那雄胺片)、观察组(盐酸特拉唑嗪+非那雄胺片)66例。比较两组总疗效率、前列腺体积、IPSS评分、控尿功能、炎性因子[白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]、前列腺特异抗原(PSA)、总前列腺特异抗原(tPSA)及不良反应。结果 观察组总疗效率、控尿率高于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组前列腺体积、IPSS评分、IL-6、TNF-α、PSA及tPSA水平均低于对照组,差异均有统计学意义(P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论 使用盐酸特拉唑嗪联合非那雄胺片治疗BPH患者总疗效率高,可显著改善患者控尿功能,调节炎性因子,降低PSA及tPSA水平,且用药安全性可靠。
Objective To analyze the effects of terazosin hydrochloride combined with finasteride tablets on clinical efficacy,urinary control function and inflammatory factors in patients with benign prostatic hyperplasia(BPH).Methods A total of 129 patients with benign prostatic hyperplasia were admitted to Chengdu Jinsha Hospital from July 2019 to January 2023.They were divided into two groups based on their treatment methods:a control group of 63 cases(finasteride tablets)and an observation group of 66 cases(tera-zosin hydrochloride+finasteride tablets).The overall efficacy rate,prostate volume,IPSS score,urinary con-trol function,inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)],prostate-specif-ic antigen(PSA),total prostate-specific antigen(tPSA)and adverse reactions were compared between the two groups.Results The total curative effect rate and urinary control rate of the observation group were high-er than those of the control group,and the differences were statistically significant(P<0.05).After treatment,the prostate volume,IPSS score,IL-6,TNF-α,PSA and tPSA levels in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no sig-nificant difference in adverse reactions between the two groups(P>0.05).Conclusion Terazosin hydrochlo-ride combined with finasteride tablets in the treatment of BPH patients has shown a high overall efficacy rate.This treatment can significantly improve urinary control function,regulate inflammatory factors,and reduce leveld of PSA and tPSA.The drug is considered safe and reliable.
作者
杨淑媛
王印
马兰
余美霖
廖先花
YANG Shuyuan;WANG Yin;MA Lan;YU Meilin;LIAO Xianhua(Department of Pharmacy,Chengdu Jinsha Hospital,Chengdu,Sichuan,China,610000;Department of Pharmacy,Chengdu Women and Children Hospital,Chengdu,Sichuan,China,610000;Department of Pharmacy,Shanghai Gaobo Cancer Hospital,Shanghai,China,200120)
出处
《分子诊断与治疗杂志》
2024年第2期370-373,378,共5页
Journal of Molecular Diagnostics and Therapy
基金
四川省科技计划项目(2022YJ0217)。
